| Methods |
Pilot study (N=11) RCT. |
| Participants |
Adults with EE. |
| Interventions |
Up to four doses of mepolizumab compared to placebo group. |
| Outcomes |
Quote: "assessed clinically, endoscopically, histologically and via biomarkers of inflammation". |
| Notes |
Funded by GlaxoSmithKline. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Reported as randomised with no further detail. |
| Allocation concealment? |
Unclear risk |
Not reported. |
| Blinding?
All outcomes |
Low risk |
Reported as double‐blind with no further detail. |
| Incomplete outcome data addressed?
All outcomes |
Unclear risk |
The results for all participants, in the groups they were randomised to, are not fully reported in the results section of this report. |
| Free of selective reporting? |
High risk |
Methods report that participants were assessed clinically, endoscopically, histologically and via biomarkers of inflammation, however only results for esophageal eosinophil count and swallowing difficulties are reported. It is unclear what the biomarkers of inflammation were or how they were measured; this is not reported. |
| Free of other bias? |
Unclear risk |
This is conference abstract and insufficent information was reported to make a judgement. |
